Corvus Pharmaceuticals Inc (CRVS)

[PatBoone]

Top line data for the 7 patients with ALC > 900 should be available and presented at the ICML conference mid June. Until then, there will be lots of volatility in CRVS. Hold on to your panty hoses. And shortly thereafter they should have that meeting with the FDA to discuss the registrational randomized Phase 3 study; if the data confirm the blocking of Th2/Th17 and skewing toward Th1 hypothesis, which requires patients to have ALC > 900 to be responsive and beneficial on treatment with CPI-818, then the share price should appreciate to the $10’s by end of the year for them to raise much needed fund to complete the registrational Phase 3 study. Partnership with a big partner could also work, if the financials make sense. With the kind of data in refractory PTCL that would be competitive with CHOP in frontline, hedge funds will jump into CRVS. That should be fun for all CRVS longs. Any potential application in autoimmune like atopic dermatitis can be pursued once CRVS has a far better financial health.